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Bongkrekic acid (BKA), isolated from Burkholderia cocovenenans, is known to 
specifically inhibit the mitochondrial ADP/ATP carrier.  However, the manner of its 
interaction with the carrier remains elusive.  In the present study, we tested the 
inhibitory effects of 17 bongkrekic acid analogues, derived from the intermediates 
obtained during its total synthesis, on the mitochondrial ATP/ATP carrier.  Rough 
screening of these chemicals, done by measuring their inhibitory effects on the 
mitochondrial ATP synthesis, revealed that 4 of them, KH-1, 7, 16, and 17, had 
moderate inhibitory effects.  Further characterization of the actions of these 4 
analogues on mitochondrial function showed that KH-16 had moderate; KH-1 and 
KH-17, weak; and KH-7, negligible side effects of both permeabilization of the 
mitochondrial inner membrane and inhibition of the electron transport, indicating that 
only KH-7 had a specific inhibitory effect on the mitochondrial ADP/ATP carrier.  
Although the parental bongkrekic acid showed a strong pH dependency of its action, the 
inhibitory effect of KH-7 was almost insensitive to the pH of the reaction medium, 
indicating the importance of the 3 carboxyl groups of BKA for its pH- dependent action.  
A direct inhibitory effect of KH-7 on the mitochondrial ADP/ATP carrier was also 
clearly demonstrated.   
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Most of the cellular ATP is synthesized by the process of oxidative phosphorylation in 
the mitochondria.  During this process, energy of nutrient molecules is first converted 
into an electrochemical gradient of H
+
 across the inner mitochondrial membrane.  
Then, using the electrochemical gradient of H
+
 across this membrane as a driving force, 
ATP is synthesized by FoF1-ATP synthase.  Therefore, to enable effective energy 
conversion, permeability of the inner mitochondrial membrane must be kept very low.  
However, various molecules such as those involved in the process of ATP synthesis or 
in the TCA cycle or β-oxidation must be conveyed across the inner mitochondrial 
membrane.  The transport of various metabolites and ions across this inner membrane 
are known to be catalyzed by transporters specific for each individual metabolite.  
These transporters are thought to have arisen from a common ancestral gene, because 
they show structural similarities such as 6-times membrane spanning topology, and so 
they are referred to as the mitochondrial solute carrier family, SLC25a.   
The ADP/ATP carrier has been the most extensively studied member of this solute 
carrier family (for recent review, see refs. (1-4)).  It was identified in 1964/65 (5-7), 
and its primary structure was determined in 1982 (8).  Two decades later, in 2002, its 
crystal structure was revealed (9).  Despite extensive studies, the catalytic mechanism 
of the ADP/ATP carrier still remains elusive.  It is thought that the ADP/ATP carrier 
catalyzes the transports of ADP and ATP by changing its conformation between that 
facing the cytosolic side (c-state) and that facing the matrix side (m-state).  Key 
molecules for understanding the catalytic mechanism of this carrier are two specific 
inhibitors of it, i.e., carboxyatractyloside (CATR) and bongkrekic acid (BKA), isolated 
as toxins from Atractylis gummifera and Burkholderia cocovenenans, respectively (10).  
These two inhibitors bind to the ADP/ATP carrier from the cytosolic side and matrix 
side, respectively, and fix the carrier in the c-state and m-state, respectively.  Therefore, 
studies on the interaction between the ADP/ATP carrier and these inhibitors are 
expected to be effective for understanding the molecular mechanism of this nucleotide 
exchange.  The detailed manner of interaction of the ADP/ATP carrier with CATR has 
been clarified by structural analysis of their co-crystal (9); however, that with BKA 
remains elusive.   
For a better understanding of the interaction of the ADP/ATP carrier with BKA, studies 
on the actions of BKA analogues should be helpful.  Thus, in the present study, we 
examined the effects of a variety of BKA analogues, derived from the intermediates 
obtained during the process of BKA synthesis, on mitochondrial functions and the 
ADP/ATP carrier.  
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Materials and methods 
 
Chemicals and reagents 
Authentic BKA was provided by Prof. Hans J. Duine (Delft University, The 
Netherlands).  [2,8-
3
H] adenosine 5'-diphosphate (code NET241), hereafter referred to 
just as [
3
H]ADP, was purchased from PerkinElmer, Inc.  
The BKA analogues, compounds KH-1~14, summarized in Fig. 1A and Table I, were 
prepared as indicated below (see also ref. 11 and Schemes 1 and 2).  The method for 
synthesis of KH-15, 16, and 17 was already reported previously (12). 
 





C-NMR spectra were recorded using a JEOL JNM AL-400 spectrometer 
(400 and 100 MHz). The IR spectra were recorded on a Shimadzu FT/IR-8300 
spectrometer using a KBr disk or a NaCl cell. Mass spectra were obtained on a JEOL 
JMS-700. Column chromatography was performed on silica gel (Kanto Chemical Co.). 
Thin-layer chromatography was performed on pre-coated plates (0.25 mm, silica gel 
Merck 60 F254). Reaction mixtures were stirred magnetically. 
 
8-((tert-butyldiphenylsilyl)oxy)octan-1-ol (13a)  
To a solution of 1.8-octanediol (10 g, 68.4 mmol) in CH2Cl2 (230 ml) was added 
imidazole (5.60 g, 82.1mmol) and TBDPSCl (13.1 g ,47.8mmol). The reaction mixture 
was stirred at rt for 12 h, and added sat,NaHCO3 aq, extracted with CH2Cl2, washed with 
brine, dried over MgSO4. The crude product was purified by silica gel column 
chromatography (Hexane/EtOAc=4/1) to give colorless oil (9.81 g, 37 %). :
1
H-NMR 
(400MHz in CDCl3) δ: 1.05 (s, 9H), 1.20-1.29 (m, 7H), 1.52-1.59 (m, 5H), 3.61-3.67 (m, 
4H), 7.26-7.44 (m, 6H), 7.68 (m, 4H) ; 
13
C-NMR (100 MHz, CDCl3) δ: 19.1, 25.6, 25.7, 
25.8, 26.8, 29.3, 32.5, 32.7, 62.8, 63.9, 127.5, 129.4, 134.0, 135.5; IR (Neat): 3342, 





To a solution of Oxalyl chloride (2.70 ml, 31.2 mmol) in CH2Cl2 (70 ml) was added 
DMSO (2.77 ml, 39.0 mmol) at -78
o
C. and stirred for 20 min, and alcohol (5.0 g ,13.0 
mmol) in CH2Cl2 (10 ml) was added at -78
o
C. The reaction mixture stirred at -78
o
C for 
20 min, and NEt3 (13.5 ml, 96.2 mmol) was added at -78
o
C. The mixture was stirred at 
rt for 1 h, and quenched with sat,NaHCO3 aq., extracted with CH2Cl2, washed with brine, 
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dried over MgSO4. The crude product was purified by silica gel column 
chromatography (Hexane/EtOAc =5 : 1) to give a yellow oil. (4.32 g, 87 %): 
1
H-NMR 
(400MHz in CDCl3) δ: 1.03 (s, 9H), 1.23-1.30 (m, 8H),1.52-1.61 (m, 2H), 2.41 (m, 2H), 




To a suspension of CrCl2 (5.77 g, 47.0 mmol) and LiI (4.20 g, 31.4 mmol) in THF (20 
ml) was added pinacol borane (2.48 g, 11.8 mmol) in THF (10 ml) and aldehyde (3.00 g, 
7.84 mmol) in THF (10 ml). The mixture was stirred at rt for 3 h, and added 
sat.NaHCO3 aq, extracted with EtOAc, washed with brine,dried over MgSO4. The crude 
product was purified by silica gel column chromatography (Hexane/EtOAc=10/1) to 
give pale yellow oil (2.37 g, 60 %): 
1
H-NMR (400MHz in CDCl3) δ: 1.04 (s, 9H), 
1.27-1.39(m, 20H), 1.53-1.56 (m, 2H), 2.13 (q, J = 7.2 Hz, 4H), 3.64 (t, J = 6.4 Hz, 6H), 
5.42 (d, J = 18.4 Hz, 1H), 6.63 (td, J = 6.4, 18 Hz, 1H), 7.36-7.42 (m, 6H), 7.66-7.68 (m, 
4H); 
13
C-NMR (100 MHz, CDCl3) δ:19.1, 24.7, 24.8, 25.7, 26.8, 28.2, 29.4, 29.3, 32.5, 






To a suspension of Pd(PPh3)2Cl2 (225 mg, 0.32 mmol) in MeOH (4.0 ml) was added 
Segment A (540 mg, 1.89 mmol) and boronic ester (800 mg, 1.58 mmol) at rt. The 
mixture stirred at rt for 10 min, and NEt3 (1.55 ml, 11.0 mmol) was added. The reaction 
mixture was stirred at rt for 6 h, and evaporated. The crude product was purified by 
silica gel column chromatography (Hexane/EtOAc=2/1) to give a yellow oil (626 mg, 
74 %): 
1
H-NMR (400MHz in CDCl3) δ: 1.05 (s, 9H), 1.25-1.28(m, 4H), 1.35-1.42 (m, 
2H), 1.53-1.58 (m, 4H), 2.21 (q, J = 7.6 Hz, 2H), 2.63 (t, J = 6.4 Hz, 2H), 3.48 (s, 3H), 
3.65 (t, J = 6.6 Hz, 2H), 3.79 (q, J = 6.8Hz, 2H), 5.28 (s, 2H), 5.69 (s, 1H),6.22 (td, J = 
7.6 Hz, 16.4 Hz, 1H), 7.36-7.44 (m, 6H), 7.53 (d, J = 16.4 Hz, 1H), 7.66-7.68 (m, 4H) ; 
13
C-NMR (100 MHz, CDCl3) δ:19.1, 25.6, 26.8, 28.9, 29.0, 29.2, 32.4, 33.4, 37.5, 57.5, 
61.8, 63.9, 89.8, 115.7, 126.5, 127.5, 129.4, 134.0, 135.5, 140.0, 153.1, 165.4; IR 





odec-4-enoic acid (KH-3, 17a) 
To a solution of alcohol (200 mg, 0.371 mmol) in CH2Cl2 (14.8 ml) was added DMP 
Page 5 of 45
Chemical Biology & Drug Design - Manuscript Copy


































































(314 mg, 0.742 mmol). The reaction mixture was stirred at rt for 0.5 h, and added sat. 
Na2S2O3 aq., extracted with CH2Cl2, washed with brine, dried over MgSO4 and give a 
crude product.  
To a solution of the crude product in tBuOH/THF/2-methyl-2-butene =3/1 /1 (7.6 ml) 
was added NaClO2 (43 mg, 0.47 mmol) and NaH2PO4・2H2O (103 mg, 0.66 mmol) in 
H2O (7.6 ml). The reaction mixture was stirred at rt for 0.5 h, and extracted with EtOAc, 
washed with brine,dried over MgSO4. The crude product was purified by silica gel 
column chromatography (Hexane/EtOAc=2/1) to give colorless oil (180 mg, 87 %): 
1
H-NMR (400MHz in CDCl3) δ: 1.04 (s, 9H), 1.24-1.28(m, 6H), 1.42 (brs, 2H), 
1.53-1.54 (m, 2H), 2.22 (q, J = 7.2 Hz, 2H), 3.38 (s, 2H), 3.48 (s, 3H), 3.65 (t, J = 6.6 
Hz, 2H), 3.65 (t, J = 6.8Hz, 2H), 5.29 (s, 1H), 5.74 (s, 2H),6.22 (td, J = 7.2 Hz, 16.4 Hz, 
1H), 7.36-7.44 (m, 6H), 7.56 (d, J = 16.4 Hz, 1H), 7.67 (m, 4H); 
13
C-NMR (100 MHz, 
CDCl3) δ:19.1, 25.4, 26.8, 28.6, 28.8, 28.9, 32.2, 33.4, 40.0, 57.6, 64.0, 90.1, 118.1, 
126.3, 127.6, 129.5, 133.9, 135.6, 140.8, 147.7, 165.0; IR (Neat): 3244, 2930, 2856, 




(Z)-3-((E)-9-((tert-butyldiphenylsilyl)oxy)non-1-en-1-yl)pent-2-enedioic acid (KH-1, 
18a) 
To a solution of ester (10 mg, 0.018 mmol) in Et2O (1.7 ml) was added MgBr2 (33 g, 
0.18mmol). The reaction mixture was stirred at rt for 20 min, and added 3M HCl and 
H2O, extracted with EtOAc, washed with brine, dried over MgSO4. The crude product 
was purified by silica gel column chromatography (CHCl3/MeOH=/19/1) to give 
colorless solid (5.7 mg, 62 %):
1
H-NMR (400MHz in CDCl3) δ: 1.04 (s, 9H), 
1.23-1.28(m, 6H), 1.41 (brs, 2H), 1.52-1.54 (m, 2H), 2.21 (q, J = 7.6 Hz, 2H), 3.38 
(s,2H), 3.65 (t, J = 13.6 Hz, 2H), 5.73 (s,1H), 6.22 (td, J = 7.2, 16.0 Hz, 1H), 7.36-7.42 
(m, 6H), 7.51 (d, J = 15.6 Hz, 1H), 7.67 (m, 4H) ; 
13
C-NMR (100 MHz, CDCl3) 
δ:20.0, 26.8, 27.3, 29.9, 30.1, 30.2, 33.5, 34.3, 41.2, 65.0, 119.8, 127.9, 128.7, 130.8, 





To a solution of 1.10-decanediol (10 g, 58.0 mmol) in CH2Cl2 (290 ml) was added 
imidazole (4.73 g, 69.6mmol) and TBDPSCl (9.56 g ,34.8mmol). The reaction mixture 
was stirred at rt for 40 min, and added sat,NaHCO3 aq, extracted with CH2Cl2, washed 
with brine, dried over MgSO4. The crude product was purified by silica gel column 
chromatography (Hexane/EtOAc=4/1) to give colorless oil (5.39 g, 23 %): 
1
H-NMR 
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(400 MHz in CDCl3) δ: 1.04 (s, 9H), 1.26 (brs, 16H), 3.62-3.3.67 (m, 4H), 7.37-7.7.42 
(m, 6H), 7.65-7.68 (m, 4H); 
13
C-NMR (100 MHz, CDCl3) δ: 19.1, 25.7, 26.8, 29.3, 29.4, 





To a solution of Oxalyl chloride (2.60 ml, 30.2 mmol) in CH2Cl2 (74 ml) was added 
DMSO (2.68 ml, 37.8 mmol) at -78
o
C. and stirred for 20 min, and alcohol (5.22 g ,12.6 
mmol) in CH2Cl2 (10 ml) was added at -78
o
C. The reaction mixture stirred at -78
o
C for 
20 min, and NEt3 (7.47 ml, 53.2 mmol) was added at -78
o
C. The mixture was stirred at 
rt for 1 h, and quenched with sat,NaHCO3 aq., extracted with CH2Cl2, washed with brine, 
dried over MgSO4. The crude product was purified by silica gel column 
chromatography (Hexane/EtOAc =4 : 1) to give a yellow oil. (4.27 g, 83 %) :
1
H-NMR 
(400MHz in CDCl3) δ: 1.04 (s, 9H), 1.26 (brs, 12H), 1.52-1.62 (m, 3H), 2.41 (m, 2H), 




 To a suspension of CrCl2 (4.60 g, 37.4 mmol) and LiI (4.56 g, 34.1 mmol) in THF (50 
ml) was added pinacol borane (3.58 g, 17.0 mmol) in THF (10 ml) and aldehyde (3.50 g, 
8.52 mmol) in THF (15 ml). The mixture was stirred at rt for 14 h, and added 
sat.NaHCO3 aq, extracted with EtOAc, washed with brine,dried over MgSO4. The crude 
product was purified by silica gel column chromatography (Hexane/EtOAc=10/1) to 
give yellow oil (2.03 g, 44 %): 
1
H-NMR (400MHz in CDCl3) δ: 1.04 (s, 9H), 
1.24-1.57(m, 26H), 2.13 (m, 2H), 3.64 (t, J = 6.4 Hz, 2H), 5.42 (d, J = 18.1 Hz, 1H), 
6.63 (td, J = 6.5, 17.8 Hz, 1H), 7.35-7.44 (m, 6H), 7.65-7.68 (m, 4H);
 13
C-NMR 
(100 MHz, CDCl3) δ: 19.1, 24.7, 25.6, 26.8, 28.1, 29.0, 29.1, 32.5, 35.7, 63.8, 82.8, 
127.5, 129.4, 134.0, 135.5, 154.6; IR (Neat): 2929, 2858, 1637, cm
-1




To a suspension of Pd(PPh3)2Cl2 (204 mg, 0.29 mmol) in MeOH (3.3 ml) was added 
Segment A (497 mg, 1.74 mmol) and . Boronic ester (800 g, 1.45 mmol) at rt. The 
mixture stirred at rt for 10 min, and NEt3 (1.44 ml, 10.2 mmol) was added. The reaction 
mixture was stirred at rt for 3 h, and evaporated. The crude product was purified by 
silica gel column chromatography (Hexane/EtOAc=2/1) to give a yellow oil (414 mg, 
50 %): 
1
H-NMR (400MHz in CDCl3) δ: 1.04 (s, 9H), 1.16-1.60 (m, 14H), 2.20 (q, J = 
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6.8 Hz, 2H), 2.63 (t, J = 6.4 Hz, 2H), 3.42 (s, 3H), 3.65 (t, J = 6.5 Hz, 2H), 3.79 (q, J = 
6.8Hz, 2H), 5.28 (s, 1H), 5.69 (s, 2H),6.22 (td, J =6.8, 16.0 Hz, 1H), 7.30-7.44 (m, 6H), 
7.48 (d, J = 16.2 Hz, 1H), 7.67 (m, 4H); 
13
C-NMR (100 MHz, CDCl3) δ:19.1, 25.7, 26.8, 
28.9, 29.1, 29.2, 29.3, 29.4, 32.5, 33.4, 37.5, 57.5, 61.8, 63.9, 89.8, 115.7, 126.5, 127.5, 




xadec-4-enoic acid (KH-6, 17b) 
To a solution of alcohol (30 mg,0.053 mmol) in CH2Cl2 1.1ml) was added DMP (45 mg, 
0.11 mmol). The reaction mixture was stirred at rt for 1 h, and added sat. Na2S2O3 aq., 
extracted with CH2Cl2, washed with brine, dried over MgSO4 and give a crude product.  
To a solution of the crude product in tBuOH/THF/2-methyl-2-butene =3/1 /1 (1.1 ml) 
was added NaClO2 (24 mg, 0.27 mmol) and NaH2PO4・2H2O (58 mg, 0.37 mmol) in 
H2O (1.1 ml). The reaction mixture was stirred at rt for 1 h, and extracted with EtOAc, 
washed with brine,dried over MgSO4. The crude product was purified by silica gel 
column chromatography (Hexane/EtOAc=2/1) to give colorless oil (17 mg, 
55 %):
1
H-NMR (400MHz in CDCl3) δ: 1.04 (s, 9H), 1.26-1.28 (m, 10H), 1.43 (brs, 2H), 
1.51-1.56 (m, 2H), 2.22 (q, J = 6.8 Hz, 2H), 3.38 (s, 2H), 3.48 (s, 3H), 3.65 (t, J = 6.6 
Hz, 2H), 5.28 (s, 2H), 5.74 (s, 1H), 6.20 (td, J = 6.8 Hz, 16.8 Hz, 1H), 7.35-7.44 (m, 
6H), 7.56 (d, J = 16 Hz, 1H), 7.68 (m, 4H) ;
 13
C-NMR (100 MHz, CD3OD) δ: 20.0, 26.8, 
27.4, 29.9, 30.2, 30.3, 30.4, 30.6, 33.6, 34.4, 57.7, 65.0, 90.9, 118.6, 127.7, 128.7, 130.8, 
135.1, 136.6, 141.3, 150.6, 166.6, 174.1; IR (Neat): 3512, 2929, 1716, 1633, 1602 cm
-1
; 
Mass (FAB) m/z 581 (M
+




To a solution of ester (84 mg, 0.14 mmol) in Et2O (11 ml) was added MgBr2 (258 g, 
0.14 mmol). The reaction mixture was stirred at rt for 20 min, and added 3M HCl and 
H2O, extracted with EtOAc, washed with brine, dried over MgSO4. The crude product 
was purified by silica gel column chromatography (CHCl3/MeOH=/19/1) to give 
colorless solid (37.7 mg, 50 %): 
1
H-NMR (400MHz in CDCl3) δ: 1.04 (s, 9H), 
1.21-1.41 (m, 10H), 1.41 (brs, 2H), 1.53-1.56 (m, 2H), 2.21 (q, J = 6.8 Hz, 2H), 3.37 
(s,2H), 3.65 (t, J = 6.6 Hz, 2H), 5.72 (s,1H), 6.22 (dt, J = 7.2, 16.0 Hz, 1H), 7.36-7.42 
(m, 6H), 7.50 (d, J = 16.4 Hz, 1H), 7.67 (m, 4H); 
13
C-NMR (100 MHz, CD3OD) δ: 19.2, 
25.7, 26.9, 28.8, 29.2, 29.3, 29.4, 32.5, 33.5, 40.3, 64.0, 117.9, 126.3, 127.5, 129.4, 
134.1, 135.6, 141.5, 148.9, 171.2, 176.2; IR (Neat): 3497, 2926, 2852, 1699, 1631, 1606 
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To a solution of 1.12-dodecanediol (5.00 g, 24.7 mmol) in CH2Cl2 was added imidazole 
(2.01 g, 29.6 mmol) and TBDPSCl (4.75 g ,17.3mmol).The reaction mixture was stirred 
at rt for 2 h, and added sat,NaHCO3 aq, extracted with CH2Cl2, washed with brine, dried 
over MgSO4. The crude product was purified by silica gel column chromatography 
(Hexane/EtOAc=3/1) to give colorless oil (3.83 g, 35 %): 
1
H-NMR (400MHz in CDCl3) 
δ: 1.05 (s, 9H), 1.25-1.31(m, 18H), 1.53-1.57 (m, 6H), 3.65 (t, J = 6.6 Hz, 4H), 
7.36-7.42 (m, 6H), 7.67 (m, 4H) :
13
C-NMR (100 MHz, CDCl3) δ:19.2, 25.7, 26.8, 29.3, 
29.4, 29.5, 29.6, 32.5, 32.7, 63.0, 64.0, 127.5, 129.4, 134.1, 135.5; IR (Neat): 3336, 




To a solution of Oxalyl chloride (0.95 ml, 11.0 mmol) in CH2Cl2 (30 ml) was added 
DMSO (0.97 ml, 13.7 mmol) at -78
o
C. and stirred for 20 min, and alcohol 13c (2.02 
g ,4.58 mmol) in CH2Cl2 (10 ml) was added at -78
o
C. The reaction mixture stirred at 
-78
o
C for 20 min, and NEt3 (4.83 ml, 34.4 mmol) was added at -78
o
C. The mixture was 
stirred at rt for 1 h, and quenched with sat,NaHCO3 aq., extracted with CH2Cl2, washed 
with brine, dried over MgSO4. The crude product was purified by silica gel column 
chromatography (Hexane/EtOAc =4 : 1) to give a yellow oil. (1.86 g, 93 %): 
1
H-NMR 
(400MHz in CDCl3) δ: 1.07 (s, 9H), 1.25-1.29 (m, 15H), 1.52-1.64 (m, 7H), 2.42 (t, J = 
8.0 Hz, 2H), 3.65 (t, J = 6.6 Hz, 2H), 7.36-7.44 (m, 6H), 7.67 (m, 4H), 9.76 (t, J = 4.0 




 To a suspension of CrCl2 (4.05 g, 33.0 mmol) and LiI (2.94 g, 22.0 mmol) in THF (50 
ml) was added pinacol borane 11 (2.20 g, 11.0 mmol) in THF (5.0 ml) and aldehyde 14c 
(2.41 g, 5.50 mmol) in THF (5.0 ml). The mixture was stirred at rt for 3 h, and added 
sat.NaHCO3 aq, extracted with EtOAc, washed with brine,dried over MgSO4. The crude 
product was purified by silica gel column chromatography (Hexane/EtOAc=10/1) to 
give yellow oil (1.87 g, 60 %): 
1
H-NMR (400MHz in CDCl3) δ: 1.04 (s, 9H), 
1.26-1.42(m, 28H), 1.52-1.59 (m, 2H), 2.14 (q, J = 6.8 Hz, 4H), 3.65 (t, J = 6.6 Hz, 6H), 
5.42 (d, J = 18.4 Hz, 1H), 6.63 (td, J = 6.8, 18.0 Hz, 1H), 7.36-7.43 (m, 6H), 7.66-7.68 
(m, 4H) 01-193 ;
13
C-NMR (100 MHz, CDCl3) δ:19.2, 24.7, 25.7, 26.8, 28.1, 29.2, 29.3, 
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29.4, 29.5, 29.6, 32.5, 35.8, 63.9, 82.9, 127.5, 129.4, 134.1, 135.5, 154.8 ; IR (Neat): 






To a suspension of Pd(PPh3)2Cl2 (250 mg, 0.36 mmol) in MeOH (20 ml) was added 
Segment A (560 mg, 1.96 mmol) and . Boronic ester 15c (1.00 g, 1.78 mmol) at rt. The 
mixture stirred at rt for 10 min, and NEt3 (1.76 ml, 12.5 mmol) was added. The reaction 
mixture was stirred at rt for 3 h, and evaporated. The crude product was purified by 
silica gel column chromatography (Hexane/EtOAc=2/1) to give a yellow oil (781 mg, 
73 %): 
1
H-NMR (400MHz in CDCl3) δ: 1.05 (s, 9H), 1.20-1.28 (m, 9H), 1.39-1.42 
(m,3H), 1.53-1.58 (m, 6H), 2.22 (q, J = 7.6 Hz, 2H), 2.63 (t, J = 6.6 Hz, 2H), 3.48 (s, 
3H), 3.65 (t, J =7.0 Hz, 2H), 3.78 (q, J = 6.6Hz, 2H), 5.28 (s, 2H), 5.68 (s, 1H),6.22 (dt, 
J = 6.8 Hz, 16.4 Hz, 1H), 7.36-7.44 (m, 6H), 7.53 (d, J = 16.0 Hz, 1H), 7.67 (m, 4H);
 
13
C-NMR (100 MHz, CDCl3) δ:19.1, 25.7, 26.8, 28.9, 29.2, 29.3, 29.4, 29.5, 32.5, 33.5, 
37.5, 57.5, 61.8, 64.0, 89.8, 115.7, 126.5, 127.5, 129.4, 134.1, 135.5, 140.1, 153.1, 





xadec-4-enoic acid (KH-9, 17c) 
To a solution of alcohol 16c (200 mg, 0.336 mmol) in CH2Cl2 (6.7 ml) was added DMP 
(570 mg, 1.34 mmol). The reaction mixture was stirred at rt for 1 h, and added sat. 
Na2S2O3 aq., extracted with CH2Cl2, washed with brine, dried over MgSO4 and give a 
crude product.  
To a solution of the crude product in tBuOH/THF/2-methyl-2-butene =3/1 /1 (6.7 ml) 
was added NaClO2 (152 mg, 1.69 mmol) and NaH2PO4・2H2O (368 mg, 2.36 mmol) in 
H2O (6.7 ml). The reaction mixture was stirred at rt for 1 h, and extracted with EtOAc, 
washed with brine,dried over MgSO4. The crude product was purified by silica gel 
column chromatography (Hexane/EtOAc=2/1) to give colorless oil (173 mg, 
86 %):
1
H-NMR (400MHz in CDCl3) δ: 1.04 (s, 9H), 1.24-1.31( m, 12H), 1.43 (brs, 2H), 
1.53-1.58 (m,4H), 2.20 (q, J = 7.2 Hz, 2H), 3.38 (s, 2H), 3.48 (s, 3H), 3.65 (t, J = 6.6 Hz, 
2H), 5.28 (s, 2H), 5.74 (s, 1H), 6.20 (dt, J = 6.8 Hz, 16 Hz, 1H), 7.36-7.42 (m, 6H), 7.56 
(d, J = 16.4 Hz, 1H), 7.67 (m, 4H) ; 
13
C-NMR (100 MHz, CD3OD) δ: 20.0, 26.9, 27.4, 
29.9, 30.2, 30.3, 30.5, 30.6, 30.7, 33.6, 34.4, 41.1, 57.7, 65.0, 90.9, 118.6, 127.8, 128.7, 
130.8, 135.1, 136.7, 141.3, 150.6, 166.7, 174.0; IR (Neat): 3292, 2933, 2854, 1710, 
1635,1602 cm
-1
; Mass (FAB) m/z 631 (M
+
+Na); HRMS calcd for C36H52NaO6Si: 
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To a solution of ester 17c (56 mg, 0.092 mmol) in Et2O (7.0 ml) was added MgBr2 (102 
mg, 0.55 mmol). The reaction mixture was stirred at rt for 20 min, and added 3M HCl 
and H2O, extracted with EtOAc, washed with brine, dried over MgSO4. The crude 
product was purified by silica gel column chromatography (CHCl3/MeOH=/19/1) to 
give colorless solid (30 mg, 58 %): 
1
H-NMR (400MHz in CDCl3) δ: 1.04 (s, 9H), 1.24 
(brs, 14H), 1.41-1.43 (m, 2H), 1.51-1.61 (m, 2H), 2.22 (q, J = 7.6 Hz, 2H), 3.38 (s,2H), 
3.65 (t, J = 6.6 Hz, 2H), 5.73 (s,1H), 6.22 (dt, J = 7.2, 16.0 Hz, 1H), 7.35-7.43 (m, 6H), 
7.51 (d, J = 16.4 Hz, 1H), 7.66-7.68 (m, 1H); 
13
C-NMR (100 MHz, CD3OD): 19.2, 25.8, 
26.9, 28.9, 29.2, 29.3, 29.4, 29.5, 29.6, 29.7, 33.5, 40.2, 64.1, 117.8, 126.3, 127.6, 129.4, 







 To a suspension of Pd(PPh3)2Cl2 (166 mg, 0.24 mmol) in MeOH (6.0 ml) was added 
Cyanoethylester (417 mg, 1.41 mmol) and. Boronic ester (600 g, 1.18 mmol) at rt. The 
mixture stirred at rt for 10 min, and NEt3 (1.15 ml, 8.19 mmol) was added. The reaction 
mixture was stirred at rt for 3 h, and evaporated. The crude product was purified by 
silica gel column chromatography (Hexane/EtOAc=2/1) to give a yellow oil (328mg, 
51 %):
1
H-NMR (400MHz in CDCl3) δ: 1.05 (s,9H), 1.24-1.59 (m, 10H), 2.22 (q, J = 7.6 
Hz, 2H), 2.63 (t, J = 6.6 Hz, 2H), 2.72 (t, J = 6.4 Hz, 2H), 3.65 (t, J = 6.6 Hz, 2H), 3.79 
(q, J = 6.0 Hz, 2H), 4.31 (t, J = 6.4 Hz, 2H), 5.68 (s, 1H), 6.25 (td, J = 6.8, 16.0 Hz, 1H), 
7.35-7.44 (m, 6H), 7.49 (d, J = 16.0 Hz, 1H), 7.66-7.68 (m, 4H) ; 
13
C-NMR (100 MHz, 
CDCl3) δ:18.0, 19.2, 25.6, 26.8, 28.9, 29.2, 32.4, 33.5, 37.5, 58.1, 61.8, 63.8, 63.9, 
114.9, 117.0, 126.3, 127.5, 129.4, 134.1, 135.5, 140.5, 153.7, 165.2; IR (Neat): 3419, 





adec-4-enoic acid (KH-2, 21a) 
 To a solution of alcohol (100 mg, 0.183 mmol) in CH2Cl2 (7.3 ml) was added DMP 
(233 mg, 0.549 mmol). The reaction mixture was stirred at rt for 0.5 h, and added sat. 
Na2S2O3 aq., extracted with CH2Cl2, washed with brine, dried over MgSO4 and give a 
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crude product.  
To a solution of the crude product in tBuOH/THF/2-methyl-2-butene =3/1/1 (4.0 ml) 
was added NaClO2 (91 mg, 1.01 mmol) and NaH2PO4·2H2O (229 mg, 1.47 mmol) in 
H2O (4.0 ml). The reaction mixture was stirred at rt for 0.5 h, and extracted with EtOAc, 
washed with brine,dried over MgSO4. The crude product was purified by silica gel 
column chromatography (Hexane/EtOAc=2/1) to give colorless oil (94 mg, 91 %): 
1
H-NMR (400MHz in CDCl3) δ: 1.04 (s, 9H), 1.24-1.28 (m, 6H), 1.42 (brs, 2H), 
1.52-1.54 (m, 2H),2.23 (q, J = 7.2 Hz, 2H), 2.73 (t, J = 6.2 Hz, 2H), 3.39 (s, 2H), 3.65 (t, 
J =6.0 Hz, 2H), 4.32 (t, J = 6.6 Hz, 2H), 5.74 (s,1H), 6.22 (td, J = 7.2, 15.6 Hz, 1H), 
7.36-7.44 (m, 6H), 7.52 (d, J = 16.4 Hz, 1H), 7.68 (m, 4H); 
13
C-NMR (100 MHz, 
CD3OD) δ: 18.4, 20.1, 26.8, 27.4, 29.9, 30.1, 35.5, 41.1, 59.9, 64.9, 118.4, 127.7, 128.7, 
130.8, 135.1, 136.7, 141.5. 
 
12-(tert-butyldimethylsilyloxy)dodecan-1-ol (22a) 
To a solution of 1.12-dodecanediol (5.00 g, 24.7 mmol) in CH2Cl2 was added 
imidazole (2.01 g, 29.6 mmol)  and TBSCl (2.70 g ,17.3mmol).The reaction mixture 
was stirred at rt for 2 h, and added sat,NaHCO3 aq, extracted with CH2Cl2, washed with 
brine, dried over MgSO4. The crude product was purified by silica gel column 
chromatography (Hexane/EtOAc=4/1) to give colorless oil (1.38 g, 18 %): 
1
H-NMR 
(400MHz in CDCl3) δ: 0.05 (s, 6H), 0.89 (s, 9H), 1.22 (brs, 14H), 1.46-1.51 (m, 2H), 
3.53-3.59 (m, 4H); 
13
C-NMR (100 MHz, CDCl3) δ: 18.0, 19.2, 25.7, 26.8, 29.0, 29.1, 
29.2, 29.3, 29.4, 29.5, 29.6, 32.6, 33.5, 37.5, 58.1, 61.9, 64.0, 114.9, 116.9, 126.3, 127.5, 





To a solution of Oxalyl chloride (0.39 ml, 4.56 mmol) in CH2Cl2 (15 ml) was added 
DMSO (0.40 ml, 5.70 mmol) at -78
o
C. and stirred for 20 min, and alcohol 22a (600 
mg ,1.90 mmol) in CH2Cl2 (5.0 ml) was added at -78
o
C. The reaction mixture stirred at 
-78
o
C for 20 min, and NEt3 (1.88 ml, 13.3 mmol) was added at -78
o
C. The mixture was 
stirred at rt for 1 h, and quenched with sat,NaHCO3 aq., extracted with CH2Cl2, washed 
with brine, dried over MgSO4. The crude product was purified by silica gel column 
chromatography (Hexane/EtOAc =4 : 1) to give a yellow oil. (524 g, 88 %): 
1
H-NMR 
(400MHz in CDCl3) δ: 0.05 (s, 9H), 0.89 (s, 9H), 1.27 (brs, 14H), 1.55-1.63 (m, 4H), 
2.40-2.43 (m, 2H), 3.60 (t, J = 6.0 Hz, 2H), 9.76 (m, 1H)  
 
(E)-tert-butyldimethyl(13-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)tridec-12-en
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To a suspension of CrCl2 (1.22 g, 9.96 mmol) and LiI (888 mg, 6.64 mmol) in THF 
(9.0) was added pinacol borane 11 (525 mg, 2.49 mmol) in THF (4.0 ml) and aldehyde 
24a (524 mg, 1.66 mmol) in THF (4.0 ml). The mixture was stirred at rt for 2 h, and 
added sat.NaHCO3 aq, extracted with EtOAc, washed with brine,dried over MgSO4. 
The crude product was purified by silica gel column chromatography 
(Hexane/EtOAc=10/1) to give yellow oil (524 g, 70 %): 
1
H-NMR (400MHz in CDCl3) 
δ: 0.05 (s, 6H), 0.89 (s, 9H), 1.24-1.52 (m, 30H), 2.14 (q, J = 7.2 Hz, 2H), 3.59 (t, J = 
6.6 Hz, 2H), 5.42 (d, J = 18.0 Hz, 1H), 6.63 (td, J = 6.4, 18.4 Hz, 1H); 
13
C-NMR 
(100 MHz, CDCl3) δ: 18.0, 24.4, 24.5, 25.4, 25.6, 27.8, 28.9, 29.0, 29.1, 29.2, 29.3, 29.4, 






To a suspension of Pd(PPh3)2Cl2 (32 mg, 0.046 mmol) in MeOH (1.0 ml) was added 
Segment A (72 mg, 0.25 mmol) in MeOH (1.8 ml) and . Boronic ester 25a (101 mg, 
0.23 mmol) in MeOH (1.8 ml) at rt. The mixture stirred at rt for 10 min, and NEt3 (0.23 
ml, 1.61 mmol) was added. The reaction mixture was stirred at rt for 3 h, and 
evaporated. The crude product was purified by silica gel column chromatography 
(Hexane/EtOAc=2/1) to give a yellow oil (80 mg, 74 %): 
1
H-NMR (400MHz in CDCl3) 
δ: 0.05 (s, 6H), 0.89 (s, 9H), 1.27 (s, 15H), 1.40-1.54 (m, H), 2.22 (q, J = 6.8 Hz, 2H), 
2.64 (t, J = 6.6 Hz, 2H), 3.48 (s, 3H), 3.60 (t, J = 6.8 Hz, 2H), 3.78 (q, J = 5.6 Hz, 2H), 
5.28 (s, 2H), 5.68 (s, 1H), 6.23 (td, J = 6.8, 16.4 Hz, 1H), 7.53 ( d, J = 16.0 Hz, 1H) ; IR 
(Neat): 3398, 2928, 2854, 1716, 1635, 1597cm
-1
; Mass (EI) m/z 470 (M
+
 ); HRMS 
calcd for C26H50O5Si: 470.3428 found 470.3432   
 
(3Z,4E)-16-(tert-butyldiphenylsilyloxy)-3-(2-(methoxymethoxy)-2-oxoethylidene)he
xadec-4-enoic acid (KH-10, 27a) 
To a solution of alcohol 26a (80 mg, 0.17 mmol) in CH2Cl2 (3.4 ml) was added DMP 
(288 mg, 0.68 mmol). The reaction mixture was stirred at rt for 0.5 h, and added sat. 
Na2S2O3 aq., extracted with CH2Cl2, washed with brine, dried over MgSO4 and give a 
crude product.  
To a solution of the crude product in tBuOH/THF/2-methyl-2-butene =3/1 /1 (3.4 ml) 
was added NaClO2 (78 mg, 0.866 mmol) and NaH2PO4・2H2O (187 mg, 1.20 mmol) in 
H2O (3.4ml). The reaction mixture was stirred at rt for 1.5 h, and extracted with EtOAc, 
washed with brine,dried over MgSO4. The crude product was purified by silica gel 
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column chromatography (Hexane/EtOAc=2/1) to give colorless oil (50.7 mg, 62 %): 
1
H-NMR (400MHz in CDCl3) δ: 0.05 (s, 6H), 0.88 (s, 9H), 1.24-1.52 (m, 22 H), 2.22 (q, 
J = 7.2 Hz, 2H), 3.37 (s, 2H), 3.48 (s, 3H), 3.61 (t, J = 6.6 Hz, 2H), 5.29 (s, 2H), 5.74 (s, 
1H), 6.21 (td, J = 7.2, 16.0 Hz, 1H), 7.56 (d, J = 16.0 Hz, 1H); 
13
C-NMR (100 MHz, 
CDCl3) δ: 18.2, 25.6, 28.3, 29.1, 29.2, 29.3, 29.4, 29.5, 32.7, 33.3, 37.4, 57.3, 61.6, 63.2. 
89.7, 115.5, 126.4, 139.8, 153.2, 165.4; IR (Neat): 3325, 2928, 2854, 1716, 1635 1602 
cm
-1
; Mass (EI) m/z 484 (M
+
 ); HRMS calcd for C26H48O6Si: 484.3220 found 484.3218  
 
12-(triphenylsilyloxy)dodecan-1-ol (22b) 
To a solution of 1.12-dodecanediol (5.00 g, 24.7 mmol) in CH2Cl2 was added imidazole 
(2.01 g, 29.6 mmol) and Triphenylsilyl chloride (5.01 g ,17.3mmol).The reaction 
mixture was stirred at rt for 1 h, and added H2O, extracted with CH2Cl2, washed with 
brine, dried over MgSO4. The crude product was purified by silica gel column 
chromatography (Hexane/EtOAc=4/1) to give colorless oil (2.87 g, 25 %): 
1
H-NMR 
(400MHz in CDCl3) δ: 1.23-1.29 (m, 20H), 3.64 (brs, 2H), 3.78 (t, J = 9.6 Hz, 2H), 
7.35-7.43 (m, 9H), 7.60-7.64 (m, 6H) 
13
C-NMR (100 MHz, CDCl3) δ:25.7, 29.2, 29.4, 






To a solution of Oxalyl chloride (0.45 ml ,5.21 mmol) in CH2Cl2 (15 ml) was added 
DMSO (0.46 ml, 6.51 mmol) at -78
o
C. and stirred for 20 min, and alcohol 22b (1.00 
g ,2.17 mmol) in CH2Cl2 (5.0 ml) was added at -78
o
C. The reaction mixture stirred at 
-78
o
C for 20 min, and NEt3 (2.13 ml, 15.2 mmol) was added at -78
o
C. The mixture was 
stirred at rt for 1 h, and quenched with sat. NaHCO3 aq., extracted with CH2Cl2, washed 
with brine, dried over MgSO4. The crude product was purified by silica gel column 
chromatography (Hexane/EtOAc =4 : 1) to give a yellow oil. (767 mg, 77 %): 
1
H-NMR 
(400MHz in CDCl3) δ: 1.22-1.29 (m, 16H), 1.60-1.64 (m, 4H), 2.41 (t, J = 7.4 Hz, 2H), 




To a suspension of CrCl2 (1.23 g 10.0 mmol) and LiI (892 mg, 6.68 mmol) in THF (9.0 
ml) was added pinacol borane 11 (528 mg, 2.51 mmol) in THF (4.0 ml) and aldehyde 
24b (767 mg, 1.67 mmol) in THF (4.0 ml). The mixture was stirred at rt for 3 h, and 
added sat.NaHCO3, extracted with EtOAc, washed with brine,dried over MgSO4. The 
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crude product was purified by silica gel column chromatography (Hexane/EtOAc=10/1) 
to give yellow oil (672 mg, 69 %): 
1
H-NMR (400MHz in CDCl3) δ1.21-1.40 (m, 30H), 
1.54-1.61 (m, 2H), 2.14 (q, J= 6.8 Hz, 2H), 3.78 (t, J = 6.6 Hz, 2H), 5.42 (d, J = 18.0 Hz, 
1H), 6.63 (td, J = 6.4, 18.4 Hz, 1H), 7.35-7.45 (m, 9H), 7.61-7.63 (m, 6H): 
13
C-NMR 
(100 MHz, CDCl3) δ:25.7, 28.9, 29.2, 29.3, 29.4, 29.5, 32.5, 33.5, 37.5, 57.5, 61.9, 64.0, 







To a suspension of Pd(PPh3)2Cl2 (180 mg, 0.256 mmol) in MeOH (7.0ml) was added 
Segment A (440 mg, 1.53 mmol) and . Boronic ester 25b (750 mg, 1.28 mmol) at rt. The 
mixture stirred at rt for 10 min, and NEt3 (1.26 ml, 8.96 mmol) was added. The reaction 
mixture was stirred at rt for 3 h, and evaporated. The crude product was purified by 
silica gel column chromatography (Hexane/EtOAc=2/1) to give a yellow oil (316 mg, 
40 %): 
1
H-NMR (400MHz in CDCl3) δ: 1.22-1.28 (m, 14H), 1.43 (brs, 2H), 1.54-1.62 
(m, 2H), 2.22 (q , J = 6.8 Hz, 2H), 2.63 (t, J = 6.8 Hz , 2H), 3.48 (s, 3H), 3.76-3.81 (m, 
4H), 5.27 (s, 2H), 5.68 (s, 1H), 6.22 (td, J = 6.8, 16.4 Hz, 1H), 7.35-7.45 (m, 9H), 7.53 
(d, J = 16.0 Hz, 1H), 7.61-7.63 (m, 6H); 
13
C-NMR (100 MHz, CDCl3) δ: 25.7, 28.9, 
29.2, 29.3, 29.4, 29.5, 29.6, 32.4, 33.4, 37.6, 57.4, 61.8, 63.9, 89.8, 115.6, 126.5, 127.7, 






enoic acid (KH-11, 27b) 
To a solution of alcohol 26b (100 mg, 0.161 mmol) in CH2Cl2 (3.5 ml) was added DMP 
(273 mg, 0.644 mmol). The reaction mixture was stirred at rt for 1 h, and added sat. 
Na2S2O3 aq., extracted with CH2Cl2, washed with brine, dried over MgSO4 and give a 
crude product.  
To a solution of the crude product in tBuOH/THF/2-methyl-2-butene =3/1 /1 (3.24 ml) 
was added NaClO2 (73 mg, 0.81 mmol) and NaH2PO4・2H2O (177 mg, 1.13 mmol) in 
H2O. The reaction mixture was stirred at rt for 1 h, and extracted with EtOAc, washed 
with brine,dried over MgSO4. The crude product was purified by silica gel column 
chromatography (Hexane/EtOAc=2/1) to give yellow oil (62 mg, 61 %): 
1
H-NMR 
(400MHz in CDCl3) δ: 1.22-1.26 (m, 14H), 1.43 (brs, 2H), 1.54-1.62 (m, 2H), 2.21 (q, J 
= 6.8 Hz, 2H), 3.36 (s, 2H), 3.47 (s, 3H), 3.79 (t, J = 6.6 Hz, 2H), 5.27 (s, 2H), 5.72 (s, 
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1H), 6.19 (td, J = 6.8, 16.4 Hz, 1H), 7.35-7.44 (m, 9H), 7.56 (d, J = 16.0 Hz, 1H), 
7.61-7.63 (m, 6H); 
13
C-NMR (100 MHz, CDCl3) δ: 25.7, 28.8, 29.2, 29.3, 29.4, 29.5, 
29.6, 32.5, 33.4, 40.0, 57.6, 64.0, 90.1, 118.0, 126.3, 127.8, 129.9, 134.4, 135.4, 140.8, 






To a solution of Silyl ether 27b (10 mg, 0.016 mmol) in THF (1.0 mL) were added 
TBAF (1M in THF, 32 L, 0.032 mmol) at 0 
o
C. The reaction mixture was stirred at 0 
o
C for 10 min, and quenched with sat. NH4Cl aq., extracted with EtOAc washed with 
brine,dried over MgSO4. The crude product was purified by silica gel column 
chromatography (CHCl3/MeOH=19/1) to give yellow oil (4.3 mg, 73 %): 
1
H-NMR 
(400MHz in CDCl3) δ: 1.27 (brs, 14H), 1.43 (brs, 2H), 1.54-1.56 (m, 2H), 2.23 (q, J = 
6.8 Hz, 2H), 3.37 (s, 2H), 3.48 (s, 3H), 3.65 (t, J = 6.4 Hz, 2H), 5.8 (s, 2H), 5.74 (s, 1H), 
6.20 (td, J = 7.2, 16.0 Hz, 1H), 7.56 (d, J = 16.0 Hz, 1H); 
13
C-NMR (100 MHz, CDCl3) 
δ: 25.5, 28.7, 29.0, 29.1, 29.2, 29.3, 29.4, 29.5, 32.5, 33.4, 40.1, 57.6, 63.0, 90.0, 117.9, 





To a solution of 1.12-dodecanediol (5.00 g, 24.7 mmol) in CH2Cl2 was added DMAP 
(150 mg, 1.24 mmol) and NEt3 (5.21 ml ,37.1mmol) and Trityl chloride (6.89 g, 24.7 
mmol). The reaction mixture was stirred at rt for 1 h, and added H2O, extracted with 
CH2Cl2, washed with brine, dried over MgSO4. The crude product was purified by silica 
gel column chromatography (Hexane/EtOAc=4/1) to give colorless oil (4.84 g, 
44 %):
1
H-NMR (400MHz in CDCl3) δ: 1.19-1.34 (m, 18H), 1.53-1.65 (m, 4H), 3.04 (t, 
J = 6.8 Hz, 2H), 3.64 (q, J = 5.6 Hz, 2H), 7.20-7.24 (m, 3H), 7.27-7.31 (m, 6H), 7.44 (m, 
6H); 
13
C-NMR (100 MHz, CDCl3) δ:25.7, 26.1, 29.3, 29.4, 29.5, 29.6, 29.9, 32.6, 62.6, 





To a solution of Oxalyl chloride (0.49 ml, 5.40 mmol) in CH2Cl2 (18 ml) was added 
DMSO (0.48 ml, 6.75 mmol) at -78
o
C. and stirred for 20 min, and alcohol 22c (1.00 
g ,2.25 mmol) in CH2Cl2 (5.0 ml) was added at -78
o
C. The reaction mixture stirred at 
-78
o
C for 20 min, and NEt3 (2.13 ml, 15.2 mmol) was added at -78
o
C. The mixture was 
stirred at rt for 1 h, and quenched with sat,NaHCO3 aq., extracted with CH2Cl2, washed 
with brine, dried over MgSO4. The crude product was purified by silica gel column 
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chromatography (Hexane/EtOAc =4 : 1) to give a yellow oil. (847 mg, 85 %): 
1
H-NMR 
(400MHz in CDCl3) δ: 1.25-1.29 (m, 14H), 1.61-1.64 (m, 2H), 2.41 (t, J = 4.8 Hz, 2H), 




To a suspension of CrCl2 (1.41 g, 11.46 mmol) and LiI (1.02 g, 7.64 mmol) in THF (10 
ml) was added pinacol borane 11 (603 mg, 2.86 mmol) in THF (5.0 ml) and aldehyde 
24c (846 mg, 1.91 mmol) in THF (5.0 ml). The mixture was stirred at rt for 3 h, and 
added sat.NaHCO3 aq. , extracted with EtOAc, washed with brine,dried over MgSO4. 
The crude product was purified by silica gel column chromatography 
(Hexane/EtOAc=10/1) to give yellow oil (708 g, 65 %): 
1
H-NMR (400MHz in CDCl3) 
δ: 1.23-1.42 (m, 28H), 1.57-1.65 (m, 2H), 2.06 (q, J = 6.8 Hz, 2H), 2.98 (t, J = 6.8 Hz, 
2H), 3.03 (t, J = 6.8 Hz, 2H), 5.38 (d, J = 18.4 Hz, 1H), 6.58 (td, J = 7.2, 17.2 Hz, 1H), 
7.07-7.10 (m, 3H), 7.27-7.43 (m, 6H), 7.36-7.39 (m, 6H) ; 
13
C-NMR (100 MHz, CDCl3) 
δ: 25.2, 26.7, 28.6, 29.6, 29.7, 29.8, 29.9, 30.0, 30.1, 30.4, 36.2, 57.2, 64.0, 83.3, 86.6, 







To a suspension of Pd(PPh3)2Cl2 (167 mg, 0.238 mmol) in MeOH (6.0ml) was added 
Segment A (440 mg, 1.53 mmol) in MeOH (3.0 ml) and . Boronic ester 25c (750 mg, 
1.28 mmol) in MeOH (3.0 ml) at rt. The mixture stirred at rt for 10 min, and NEt3 (1.26 
ml, 8.96 mmol) was added. The reaction mixture was stirred at rt for 3 h, and 
evaporated. The crude product was purified by silica gel column chromatography 
(Hexane/EtOAc=2/1) to give a yellow oil (113 mg, 16 %): 
1
H-NMR (400MHz in 
CDCl3) δ: 1.24-1.43 (m, 14H), 1.58-1.63 (m, 4H), 2.15 (q, J = 7.2 Hz, 2H), 2.63 (t, J = 
6.4 Hz, 2H), 3.03 (t, J = 6.6 Hz, 2H), 3.48 (s, 3H), 3.78 (q, J = 6.4 Hz, 2H), 5.27 (s, 2H), 
5.68 (s, 1H), 6.22 (dt, J = 7.6, 15.6 Hz, 1H), 7.20-7.24 (m, 3H), 7.27-7.31 (m, 6H), 7.44 
(m, 6H), 7.53 (d, J = 16.4 Hz, 1H); 
 13
C-NMR (100 MHz, CDCl3) δ: 26.2, 28.9, 29.2, 
29.4, 29.5, 29.6, 30.0, 33.5, 37.5, 86.2, 89.9, 115.7, 126.5, 126.7, 127.7, 128.7, 140.2, 





acid (KH-12 27c) 
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To a solution of alcohol 26c (112 mg, 0.187 mmol) in CH2Cl2 (4.0 ml) was added DMP 
(317 mg, 0.748 mmol). The reaction mixture was stirred at rt for 1 h, and added sat. 
Na2S2O3 aq., extracted with CH2Cl2, washed with brine, dried over MgSO4 and give a 
crude product.  
To a solution of the crude product in tBuOH/THF/2-methyl-2-butene =3/1 /1 (3.8 ml) 
was added NaClO2 (85 mg, 0.94 mmol) and NaH2PO4・2H2O (206 mg, 1.32 mmol) in 
H2O. The reaction mixture was stirred at rt for 1 h, and extracted with EtOAc, washed 
with brine,dried over MgSO4. The crude product was purified by silica gel column 
chromatography (Hexane/EtOAc=2/1) to give yellow oil (38 mg, 37 %): 
1
H-NMR 
(400MHz in CDCl3) δ: 1.24-1.65 (m, 18H), 2.21 (q, J = 7.2 Hz, 2H), 3.03 (t, J = 6.6 Hz, 
2H), 3.38 (s,2H), 3.46 (s, 3H), 5.28 (s, 2H), 5.74 (s, 1H), 6.19 (dt, J = 7.2, 16.0 Hz, 1H), 
7.20-7.24 (m, 3H), 7.27-7.30 (m, 6H), 7.44 (m, 6H), 7.56 (d, J = 16.4 Hz, 1H); 
13
C-NMR (100 MHz, CDCl3) δ: 26.2, 28.8, 29.2, 29.4, 29.5, 29.6, 30.0, 33.4, 40.0, 57.6, 
63.7, 86.2, 90.0, 118.1, 126.3, 126.8, 127.6, 128.7, 140.9, 144.5, 147.6, 165.1, 175.9 






 To a suspension of Pd(PPh3)2Cl2 (154 mg, 0.22 mmol) in MeOH (2.0 ml) was added 
Cyanoethylester (385 mg, 1.31 mmol) and . Boronic ester (600 g, 1.09 mmol) at rt. The 
mixture stirred at rt for 10 min, and NEt3 (1.10 ml, 11.0 mmol) was added. The reaction 
mixture was stirred at rt for 3 h, and evaporated. The crude product was purified by 
silica gel column chromatography (Hexane/EtOAc=2/1) to give a yellow oil (316 mg, 
50 %):
1
H-NMR (400MHz in CDCl3) δ: 1.05 (s,9H), 1.24-1.44 (m, 12H), 1.52-1.57 (m, 
2), 2.23 (q, J = 7.6 Hz, 2H), 2.63 (t, J = 6.6 Hz, 2H), 2.72 (t, J = 6.2 Hz, 2H), 3.65 (t, J 
= 6.6 Hz, 2H), 3.79 (q, J = 6.4 Hz, 2H), 4.31 (t, J = 6.4 Hz, 2H), 5.68 (s, 1H), 6.25 (td, J 
= 6.8, 16.0 Hz, 1H), 7.35-7.44 (m, 6H), 7.49 (d, J = 16.0 Hz, 1H), 7.66-7.68 (m, 4H); 
13
C-NMR (100 MHz, CDCl3) δ:18.0, 19.2, 25.7, 26.9, 28.8, 29.2, 29.3, 29.5, 32.5, 33.5, 
39.8, 58.3, 64.0, 117.2, 126.1, 127.6, 129.5, 134.1, 135.6, 141.5, 148.2, 164.9; IR 





adec-4-enoic acid (KH-5, 21b) 
 To a solution of alcohol (100 mg, 0.173 mmol) in CH2Cl2 (7.0 ml) was added DMP 
(220 mg, 0.519 mmol). The reaction mixture was stirred at rt for 1 h, and added sat. 
Na2S2O3 aq., extracted with CH2Cl2, washed with brine, dried over MgSO4 and give a 
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crude product.  
To a solution of the crude product in tBuOH/THF/2-methyl-2-butene =3/1 /1 (3.4 ml) 
was added NaClO2 (80 mg, 0.880 mmol) and NaH2PO4・2H2O (192 mg, 1.23 mmol) in 
H2O (3.4 ml). The reaction mixture was stirred at rt for 1 h, and extracted with EtOAc, 
washed with brine,dried over MgSO4. The crude product was purified by silica gel 
column chromatography (Hexane/EtOAc=2/1) to give colorless oil (98 mg, 96 %): 
1
H-NMR (400MHz in CDCl3) δ: 1.04 (s, 9H), 1.26 (s, 10H), 1.43 (brs, 2H), 1.51-1.57 
(m, 2H), 2.23 (q, J = 6.8 Hz, 2H), 2.72 (t, J = 6.6 Hz, 2H), 3.38 (s, 2H), 3.65 (t, J = 6.6 
Hz, 2H), 4.32 (t, J = 6.2 Hz, 2H), 5.73 (s,1H), 6.22 (td, J = 7.6, 16.0 Hz, 1H), 7.36-7.44 
(m, 6H), 7.52 (d, J = 16.0 Hz, 1H), 7.67 (m, 4H);
 13
C-NMR (100 MHz, CD3OD) δ:18.4, 
20.0, 26.8, 27.4, 30.0, 30.2, 30.3, 30.4, 30.6, 33.6, 34.4, 41.1, 59.9, 65.0, 118.1, 127.7, 
128.7, 130.8, 135.1, 136.7, 141.5, 150.7, 166.1, 174.1; IR (Neat): 3498, 2930, 2857, 






 To a suspension of Pd(PPh3)2Cl2 (189 mg, 0.27 mmol) in MeOH (6.0 ml) was added 
Cyanoethylester 19 (400 mg, 1.37 mmol) and . Boronic ester 15c (600 g, 1.06 mmol) at 
rt. The mixture stirred at rt for 10 min, and NEt3 (1.04 ml, 7.42 mmol) was added. The 
reaction mixture was stirred at rt for 3 h, and concentrated. The crude product was 
purified by silica gel column chromatography (Hexane/EtOAc=2/1) to give a yellow oil 
(255 mg, 42 %):
1
H-NMR (400MHz in CDCl3) δ: 1.05 (s, 9H), 1.25-1.28 (m, 14H), 
1.44-1.46 (m, 2H), 1.52-1.59 (m, 2H), 2.23 (q, J = 6.8 Hz, 2H), 2.63 (t, J = 6.6 Hz, 2H), 
2.72 (t, J = 6.4 Hz, 2H), 3.65 (t, J = 6.6 Hz, 2H), 3.79 (q, J = 6.0 Hz, 2H), 4.31 (t, J = 
6.6 Hz, 2H), 5.68 (s, 1H), 6.25 (td, J = 6.8, 16.0 Hz, 1H); 
13
C-NMR (100 MHz, CDCl3) 
δ: 18.0, 19.2, 25.7, 26.8, 29.0, 29.1, 29.2, 29.3, 29.4, 29.5, 29.6, 32.6, 33.5, 37.5, 58.1, 
61.9, 64.0, 114.9, 116.9, 126.3, 127.5, 129.4, 134.1, 135.5, 140.7, 153.7, 165.2; IR 
(Neat): 3431, 2928, 2854, 2254, 1714, 1633 cm
-1
; Mass (FAB) m/z 603 (M
+
); HRMS 
calcd for C37H53O4NSi: 603.3744 found 603.3749 
 
(3Z,4E)-14-((tert-butyldiphenylsilyl)oxy)-3-(2-(2-cyanoethoxy)-2-oxoethylidene)tetr
adec-4-enoic acid (KH-8, 21c) 
 To a solution of alcohol 20c (65 mg, 0.11 mmol) in CH2Cl2 (2.2 ml) was added DMP 
(140 mg, 0.33 mmol). The reaction mixture was stirred at rt for 1 h, and added sat. 
Na2S2O3 aq., extracted with CH2Cl2, washed with brine, dried over MgSO4 and give a 
crude product.  
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To a solution of the crude product in tBuOH/THF/2-methyl-2-butene =3/1 /1 (0.90ml) 
was added NaClO2 (41 mg, 0.46 mmol) and NaH2PO4・2H2O (99 mg, 0.64 mmol) in 
H2O (0.90 ml). The reaction mixture was stirred at rt for 1 h, and extracted with EtOAc, 
washed with brine,dried over MgSO4. The crude product was purified by silica gel 
column chromatography (Hexane/EtOAc=2/1) to give colorless oil. (45 mg, 66 %): 
1
H-NMR (400MHz in CDCl3) δ: 1.04 (s, 9H), 1.24-1.28 (s, 14H), 1.44 (brs, 2H), 
1.52-1.57 (m, 2H), 2.23 (q, J = 7.6 Hz, 2H), 2.72 (t, J = 6.4 Hz, 2H), 3.38 (s, 2H), 3.65 (t, 
J = 6.6 Hz, 2H), 4.32 (t, J = 6.2 Hz, 2H), 5.73 (s,1H), 6.22 (td, J = 6.8, 16.8 Hz, 1H), 
7.36-7.44 (m, 6H), 7.52 (d, J = 16.0 Hz, 1H), 7.67 (d, J = 8.0 Hz, 4H); 
13
C-NMR 
(100 MHz, CD3OD) δ: 18.4, 20.0, 26.8, 27.4, 29.9, 30.2, 30.3, 30.5, 30.6, 33.6, 34.4, 
41.1, 59.9, 65.0, 118.1, 118.7, 127.8, 128.7, 130.8, 135.1, 136.6, 141.5, 150.8, 166.7, 
174.2.; IR (Neat): 3466, 2928, 2857, 2254, 1739 cm
-1
; Mass (FAB) m/z 618 (M
+
 + 1); 
HRMS calcd for C37H52O5Si: 618.3615 found 618.3620   
 
12-((tert-butyldiphenylsilyl)oxy)dodecanoic acid (29) 
To a solution of aldehyde 14c in tBuOH/THF/2-methyl-2-butene = 3/ 1 / 1 (60 ml) and 
H2O (60 ml) was added NaClO2 (11.3 g, 125 mmol) and NaH2PO4・2H2O (19.5 g, 125 
mmol) . The reaction mixture was stirred at rt for 1.5 h, and extracted with EtOAc, 
washed with brine,dried over MgSO4. The crude product was purified by silica gel 
column chromatography (Hexane/EtOAc=2/1) to give colorless oil (4.97 g, 87 %): 
1
H-NMR (400MHz in CDCl3) δ: 1.05 (s, 9H), 1.24-1.31 (m, 14H), 1.53-1.63 (m, 4H), 
2.35 (t, J = 7.4 Hz, 2H), 3.65 (t, J = 6.6 Hz, 2H), 7.37-7.42 (m, 6H), 7.67 (m, 2H) ; 
13
C-NMR (100 MHz, CDCl3) δ: 19.2, 24.7, 25.7, 26.9, 29.0, 29.2, 29.3, 29.4, 29.5, 29.6, 





methoxymethyl 12-((tert-butyldiphenylsilyl)oxy)dodecanoate (30) 
To a solution of carboxylic acid 29 (4.97 g, 10.9 mmol) in CH2Cl2 was added 
diisopropylethylamine (5.27 g, 65.4 mmol) and MOMCl (7.04 g ,54.5mmol) at 0
o
C. The 
reaction mixture was stirred at rt for 1.5 h, and added sat,NaHCO3 aq, extracted with 
CH2Cl2, washed with brine, dried over MgSO4. The crude product was purified by silica 
gel column chromatography (Hexane/EtOAc=2/1) to give colorless oil (5.42 g, 99 %): 
1
H-NMR (400MHz in CDCl3) δ: 1.05 (s, 9H), 1.25-1.28 (m, 14H), 1.54-1.55 (m, 4H), 
2.36 (t, J = 7.6 Hz, 2H), 3.46 (s, 3H), 3.65 (t, J = 6.6 Hz, 2H), 5.23 (s, 2H), 7.36-7.42 (m, 
6H), 7.69-7.71 (m, 2H); 
13
C-NMR (100 MHz, CDCl3) δ: 19.1, 24.7, 25.7, 26.8, 29.0, 
29.2, 29.3, 29.5, 32.5, 34.2, 57.4, 63.9, 90.0, 127.5, 127.6, 129.4, 134.1, 135.2, 135.5 ; 
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methoxymethyl 12-hydroxydodecanoate (31) 
To a solution of ester 30 (4.97 g, 10.9 mmol) in CH2Cl2 was added 
diisopropylethylamine (5.27 g, 65.4 mmol) and MOMCl (7.04 g ,54.5mmol) at 0
o
C. The 
reaction mixture was stirred at rt for 2 h, and added sat,NaHCO3 aq, extracted with 
CH2Cl2, washed with brine, dried over MgSO4. The crude product was purified by silica 
gel column chromatography (Hexane/EtOAc=2/1) to give colorless oil (5.42 g, 99 %): 
1
H-NMR (400MHz in CDCl3) δ: 1.24-1.28 (m, 16H), 1.56-1.66 (m, 6H), 2.35 (t, J = 7.6 
Hz, 2H), 3.46 (s, 3H), 3.63 (t, J = 6.6 Hz, 2H), 5.23 (s, 2H); 
13
C-NMR (100 MHz, 
CDCl3) δ: 24.7, 25.7, 29.0, 29.2, 29.3, 29.4, 29.5, 32.7, 34.2, 57.5, 62.9, 90.1, 173.4; IR 
(Neat): 3460, 2926, 2854, 1747 cm
-1
; Mass (EI) m/z 261 (M
+
+1); HRMS calcd for 
C14H29O4: 261.1998 found 261.2073 
   
methoxymethyl 12-oxododecanoate (32) 
To a solution of Oxalyl chloride (0.24 ml, 2.76 mmol) in CH2Cl2 (10 ml) was added 
DMSO (0.24 ml, 3.45 mmol) at -78 
o
C. and stirred for 20 min, and alcohol 31 (300 
mg ,1.15 mmol) in CH2Cl2 (6.0 ml) was added at -78
o
C. The reaction mixture stirred at 
-78
o
C for 20 min, and NEt3 (1.21 ml, 8.63 mmol) was added at -78
o
C. The mixture was 
stirred at rt for 1 h, and quenched with sat,NaHCO3 aq., extracted with CH2Cl2, washed 
with brine, dried over MgSO4. The crude product was purified by silica gel column 
chromatography (Hexane/EtOAc =4 : 1) to give a yellow oil. (295 mg, 99 %): 
1
H-NMR 
(400MHz in CDCl3) δ: 1.28 (s, 13H), 1.59-1.64 (m, 3H), 2.35 (t, J = 7.4 Hz, 2H), 2.42 (t, 




 To a suspension of CrCl2 (840 mg 6.84 mmol) and LiI (610 mg, 4.56 mmol) in THF 
(4.0 ml) was added pinacol borane 11 (480 mg, 2.28 mmol) in THF (3.0 ml) and 
aldehyde 32 (295 mg, 1.14mmol) in THF (3.0 ml). The mixture was stirred at rt for 2.5h, 
and added sat.NaHCO3, extracted with EtOAc, washed with brine,dried over MgSO4. 
The crude product was purified by silica gel column chromatography 
(Hexane/EtOAc=10/1) to give green oil (140 mg, 32 %): 
1
H-NMR (400MHz in CDCl3) 
δ: 1.24-1.40 (m, 26H), 1.64-1.66 (m, 2H), 2.14 (q, J = 6.8 Hz, 2H), 2.35 (t, J = 7.4 Hz, 
2H), 3.46 (s, 3H), 5.23 (s, 2H), 5.42 (d, J = 18.4 Hz, 1H), 6.63 (td, J = 6.4, 18.4 Hz, 1H);
 
13
C-NMR (100 MHz, CDCl3) δ: 24.7, 28.1, 29.0, 29.1, 29.2, 29.3, 29.4, 29.5, 34.3, 35.8, 
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57.5, 82.9, 90.1, 154.7, 173.3 ; IR (Neat): 2928, 2854, 1745, 1637 cm
-1
; Mass (FAB) 
m/z 383 (M
+
+1); HRMS calcd for C21H40BO5: 383.2969 found 383.2973  
 
(2Z,4E)-bis(methoxymethyl) 3-(2-hydroxyethyl)hexadeca-2,4-dienedioate (34) 
To a suspension of Pd(PPh3)2Cl2 (67 mg, 0.0952 mmol) in MeOH (1.0 ml) was added 
Segment A (148mg, 0.523 mmol) and . Boronic ester 33 (182 mg, 0.476 mmol) at rt. 
The mixture stirred at rt for 10 min, and NEt3 (1.76 ml, 12.5 mmol) was added. The 
reaction mixture was stirred at rt for 3 h, and evaporated. The crude product was 
purified by silica gel column chromatography (Hexane/EtOAc=2/1) to give a yellow oil 
(195 mg, 98 %): 
1
H-NMR (400MHz in CDCl3) δ: 1.27 (brs, 12H), 1.43 (brs, 2H), 
1.63-1.66 (m, 2H), 2.21 (q, J = 7.6 Hz, 2H), 2.35 (t, J = 7.8 Hz, 2H), 2.64 (t, J = 6.6 Hz, 
2H), 3.46 (s, 3H), 3.48 (s, 3H), 3.79 (q, J = 6.4 Hz, 2H), 5.23 (s, 2H), 5.28 (s, 2H), 5.69 
(s, 1H), 6.22 (td, J = 7.2, 16.0 Hz, 1H), 7.53 (d, J = 16.4 Hz, 1H) ; 
13
C-NMR (100 MHz, 
CD3OD) δ: 24.8, 28.9, 29.0, 29.1, 29.2, 29.3, 29.4, 29.5, 33.4, 34.3, 37.5, 57.5, 61.9, 
89.7, 90.1, 115.7, 126.5, 140.1, 153.1, 165.4, 173.4 ; IR (Neat): 3444, 2926, 2854, , 
1732, 1716, 1635, 1597 cm
-1
; Mass (EI) m/z 414 (M
+
); HRMS calcd for C22H38O7: 
414.2618 found 414.2612 
 
(3Z,4E)-16-(methoxymethoxy)-3-(2-(methoxymethoxy)-2-oxoethylidene)-16-oxohex
adec-4-enoic acid (KH-14, 35) 
To a solution of alcohol 34 (100mg, 0.24 mmol) in CH2Cl2 (5.0ml) was added DMP 
(407 mg, 0.96 mmol). The reaction mixture was stirred at rt for 1 h, and added sat. 
Na2S2O3 aq., extracted with CH2Cl2, washed with brine, dried over MgSO4 and give a 
crude product.  
To a solution of the crude product in tBuOH/THF/2-methyl-2-butene =3/1 /1 (5.0 ml) 
was added NaClO2 (109 mg, 1.20mmol) and NaH2PO4・2H2O (262 mg, 1.68 mmol) in 
H2O (5.0ml). The reaction mixture was stirred at rt for 1 h, and extracted with EtOAc, 
washed with brine,dried over MgSO4. The crude product was purified by silica gel 
column chromatography (Hexane/EtOAc=2/1) to give colorless oil (38 mg, 37 %): 
1
H-NMR (400MHz in CDCl3) δ: 1.24-1.30 (m, 14H), 1.43 (brs, 2H), 1.63-1.66 (m, 2H), 
2.22 (q, J = 7.6 Hz, 2H), 2.36 (t, J = 7.4 Hz, 2H), 3.38 (s, 2H), 3.47 (s, 3H), 3.48 (s, 3H), 
5.24 (s, 2H), 5.28 (s, 2H), 5.74 (s, 1H), 6.21 (td, J = 7.6, 15.6 Hz, 1H), 7.56 (d, J = 16.0 
Hz, 1H) ; 
13
C-NMR (100 MHz, CD3OD) δ: 25.9, 29.9, 30.1, 30.2, 30.3, 30.4, 30.5, 30.6, 
34.4, 35.1, 41.0, 57.7, 90.9, 91.2, 118.6, 127.8, 141.4, 150.7, 166.7, 174.1, 174.9 ; IR 
(Neat): 3083, 2933, 2928, 2854, 1737, 1717, 1635 cm
-1
; Mass (FAB) m/z 429 (M
+
+1); 
HRMS calcd for C22H37O8: 429.2488 found 429.2498 
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Preparation of mitochondria from rat liver  
Mitochondria were prepared from the liver of 8-week-old male Wistar rats by the 
differential centrifugation procedure reported previously (13).  Final mitochondrial 
pellets were suspended in aliquots of medium containing 250 mM sucrose and 2 mM 
Tris-Cl at pH 7.4.  The resulting suspension was used as a stock solution of 
mitochondria and kept on ice during the experiments.  Its protein concentration was 
determined by the Biuret method using bovine serum albumin as a standard.   
 
Evaluation of the inhibitory effects of BKA analogues on mitochondrial ATP 
synthesis  
The velocity of ATP synthesis in the mitochondrial suspension was measured by 
measuring the change in the pH of the incubation medium (13,14).  Briefly, 
mitochondria were suspended in the appropriate amount of medium (3 mM potassium 
phosphate buffer, pH 7.4 or 6.8, containing 200 mM sucrose, 20 mM KCl, 3 mM 
MgCl2) to give a protein concentration of 0.7 mg/ml.  After the addition of 10 mM 
succinate (plus 1.25 µg/ml rotenone) as a respiratory substrate, ATP synthesis was 
started by the addition of 200 µM ADP.  The incubation time-dependent change in the 
pH of the mitochondrial suspension was monitored by using pH electrode model 
PCE108CW (Tokokagaku, Tokyo) and recorded at 25º C.  The changes in pH were 
calibrated by the addition of 100 µM oxalic acid.   
 
Evaluation of the membrane permeabilization effects of BKA analogues, and 
inhibitory effects of these analogues on the mitochondrial electron transport 
system    
The membrane permeabilization effects of the BKA analogues, and their inhibitory 
effects on the mitochondrial electron transport system were determined by measuring 
the rate of oxygen consumption by mitochondria.  For this purpose, mitochondria were 
suspended in the above-mentioned medium (pH 6.8), supplemented with 5 mM 
succinate (plus 1.25 µg/ml rotenone) as a respiratory substrate.  After the addition of a 
certain amount of individual BKA analogues, time-dependent changes in the oxygen 
concentration of the mitochondrial suspension were monitored at 25º C by using a 
Clark-type oxygen electrode (Yellow Springs Instrument, model 5331).   
 
Evaluation of the inhibitory effects of KH-7 on the mitochondrial ADP uptake  
To evaluate the direct action of KH-7 on the mitochondrial ADP/ATP carrier, we 
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measured the uptake of [
3
H]ADP into mitochondria as described previously (15).  
Briefly, mitochondria (1 mg protein) were suspended in the above-mentioned medium 
(0.5 ml, pH 7.4, not supplemented with the respiratory substrate) and incubated at 25º C 
for 2 min in the presence or absence of certain chemicals (BKA, CATR or KH-7).  
Then, a 10-µl aliquot of 2 mM ADP solution containing [
3
H]ADP (specific radioactivity 
of 185 MBq/mmol ADP) was added.  After an incubation for 10 seconds, the reaction 
was terminated by the addition of a sufficient amount of CATR to make its final 
concentration of 10 µM; and mitochondria were then pelleted by centrifugation at 
10,000 rpm for 1 min.  After complete removal of the supernatant, the mitochondrial 
pellet was solubilized with 200 µl of 1% SDS solution.  The radioactivity in 50 µl of 
the solubilized mitochondrial solution was counted in an Aloka liquid scintillation 
counter, model LSC-3500.   
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BKA analogues used in the present study  
 
BKA has 3 carboxylic acids connected by a branched chain of partially unsaturated fatty 
acid.  This structure suggested to us that the anionic functional groups such as 
carboxylate would be essential for the binding of BKA to biomolecules and that the 
fatty acid chain would control the spatial configuration of these functional groups.  
Hence, we designed a general structure for the BKA analogues used in the present study 
(Fig. 1A), one consisting of two parts, left and right.  As shown in Table I, the left part 
contained carboxylate(s) and/or an ester (R
1
) of acid-labile methoxymethyl ester or 
base-labile cyanoethyl ester, a (Z,E)-conjugated diene, and a lipophilic fatty acid chain 
of various length (n = 6, 8, 10, and 16); and the right part, a functional group of 
hydrophilic carboxy (COOH), methoxymethyl ester (methoxymethyloxycarbonyl 





BuPh2, SiPh3) or alkyl ether (CPh3).  We prepared a total of 17 BKA 
analogues and examined their effects on the mitochondrial ADP/ATP carrier.   
 
Inhibitory effects of these 17 BKA analogues on mitochondrial ATP synthesis 
 
First, we roughly tested the inhibitory effects of these 17 BKA analogues on the 
mitochondrial ADP/ATP carrier by measuring their effects on the ATP synthesis in 
isolated mitochondria.  If a certain one of these chemicals showed an inhibitory effect 
on the mitochondrial ADP/ATP carrier, import of ADP into the mitochondrial matrix 
would be suppressed; and, hence, ATP synthesis would be inhibited.  Because H
+
 is 
consumed during ATP synthesis, as shown below,  
                   ADP + Pi + H
+
 → /ATP + H2O  
 ATP synthesis in mitochondria can be determined by measuring the pH of the 
incubation medium (14).  In addition, the inhibitory effect of BKA, the parental 
compound of the chemicals used, on the mitochondrial ATP synthesis is known to be 
sensitive to the pH of the incubation medium (16).  Thus, the actions of the test 
chemicals were evaluated under two pH conditions, those of 7.4 and 6.8.  As shown in 
Fig. 2, the addition of ADP to the mitochondria suspended in medium containing 
inorganic phosphate (Pi) caused alkalinization of the incubation medium, thus reflecting 
ATP synthesis, regardless of the differences in pH of the incubation medium.  In the 
medium of pH 7.4, BKA at 1 µM had a partial inhibitory effect on the alkalinization of 
Page 25 of 45
Chemical Biology & Drug Design - Manuscript Copy


































































the incubation medium, but that at 10 µM suppressed it perfectly.  On the contrary, in 
the medium of pH 6.8, BKA was effective in suppressing the alkalinization of the 
incubation medium even at 1 µM.  As these results supported the reported 
pH-dependent action of BKA on mitochondrial ATP synthesis, i.e., stronger effects at a 
slightly acidic pH than at neutral pH (16), this experimental system was concluded to be 
suitable for evaluation of the inhibitory effects of BKA analogues on mitochondrial ATP 
synthesis; and so we adopted it for evaluating the action of the 17 BKA analogues.  
Because the inhibitory effect of BKA on the mitochondrial ATP synthesis was more 
remarkable at pH 6.8 than at pH 7.4, we tested the analogue action at pH 6.8.   
As shown in Fig. 3, the inhibitory effects of the BKA analogues on mitochondrial ATP 
synthesis were much more moderate than that effect of BKA, and no analogues showed 
perfect inhibition at 1 µM, as seen with BKA.  However, the actions of 4 of the 
analogues, i.e., KH-1, -7, -16 and -17, were relatively remarkable; and these compounds 
at 10 µM completely suppressed the alkalinization of the incubation medium.  
Therefore, we focused on these 4 BKA analogues in subsequent experiments.   
As stated above, an increase in the pH of the incubation medium reflects inhibition of 
ATP synthesis.  In the case of BKA at low concentrations, its inhibitory effect on ATP 
synthesis could be simply attributable to its inhibitory action on the ADP/ATP carrier, 
because it does not show remarkable side effects on other mitochondrial functions.  
However, when we evaluate the effects of new chemicals on mitochondrial ATP 
synthesis, we must pay adequate attention to their possible side effects that may 
influence this synthesis.  Thus, we next tested whether these analogues had any i) 
permeabilization effects on the mitochondrial inner membrane or ii) inhibitory effects 
on the mitochondrial electron transport system, because these actions are major side 
effects that would influence mitochondrial ATP synthesis.  These effects could be 
evaluated by measuring the oxygen consumption by mitochondria.   
 
Side effects of BKA analogues affecting ATP synthesis 
 
We first evaluated the permeabilization effects of BKA analogues on the mitochondrial 
inner membrane.  As shown in Fig. 4A, when mitochondria were suspended in the 
medium containing a respiratory substrate (trace “control”), gradual oxygen 
consumption, to compensate for the H
+
 leakage through the mitochondrial inner 
membrane, was observed.  The addition of 100 nM SF6847, a most effective 
protonophore (17,18), remarkably accelerated the mitochondrial oxygen consumption.  
Using these two conditions as the membrane states showing the lowest and the highest 
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 permeabilities, respectively, we examined the permeabilization effects of the 4 BKA 
analogues on the mitochondrial inner membrane.  As shown in Fig. 4B, KH-16 at 10 
µM markedly increased the rate of mitochondrial oxygen consumption, and KH-1 and 
-17 showed weak acceleration effects when tested at the same concentration.  KH-7 
also slightly accelerated the mitochondrial oxygen consumption at 10 µM, but this effect 
was almost negligible.   
We next evaluated the inhibitory effects of BKA analogues on the mitochondrial 
electron transport system.  This effect was evaluated by measuring how the rate of 
oxygen consumption stimulated by SF6847 would be inhibited by the individual BKA 
analogues.  For this purpose, mitochondria were pretreated with BKA or with KH-1, -7, 
-16 or -17 at 1 or 10 µM for 1 min, and then 100 nM SF6847 was added.  If BKA 
analogues had an inhibitory effect on the mitochondrial electron transport system, then 
the rate of oxygen consumption effected by the addition of SF6847 would be decreased.  
A typical result obtained with 10 µM BKA is shown in Fig. 5A; and a summary of the 
results obtained with the 4 BKA analogues, in Fig. 5B.  BKA itself showed moderate 
inhibitory effects on the mitochondrial electron transport system at 10 µM BKA.  
KH-7 also showed moderate inhibitory effects at 10 µM, almost to the same extent as 
observed with BKA; but the other 3 BKA analogues, KH-1, -16, and -17, showed much 
stronger effects than BKA.  However, these effects were almost negligible at the 1 µM 
concentration.  Based on these results, the inhibitory effects of KH-1, 16, and 17 on the 
mitochondrial ATP synthesis were concluded to be not simply attributable to the results 
of the specific inhibition of mitochondrial ADP/ATP carrier; but KH-7 was concluded to 
specifically inhibit mitochondrial ADP/ATP carrier without showing remarkable side 
effects on the other mitochondrial functions.   
 
pH dependency of the inhibitory effect of BKA and its analogues on  
mitochondrial ATP synthesis 
 
We next examined the pH dependency of the inhibitory effect of BKA and KH-7 on 
mitochondrial ATP synthesis.  As shown in Fig. 6 (see also Fig. 2, left traces), BKA 
showed a strong pH-dependent inhibitory effect on the ATP synthesis, and it showed 
strong inhibition, with it being stronger at a slightly acidic pH than at pH 7.4.  On the 
contrary, KH-7 showed a weak and opposite pH dependency; i.e., it was most effective 
at neutral pH (7.4) and rather weaker at the slightly acidic pH.  Therefore, KH-7 was 
concluded to have lost its parental pH dependency.  Possibly, the third carboxyl group 
present in the parental BKA but lacking in KH-7 was responsible for the pH 
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dependency of the inhibitory action of BKA.   
 
Evaluation of the direct inhibitory effects of KH-7 on the mitochondrial ADP/ATP 
carrier 
Finally, we tested the direct action of KH-7 on the mitochondrial ADP/ATP carrier by 
measuring the uptake of [
3
H]ADP.  KH-7 at lower concentrations such as 1-10 µM was 
not remarkably effective, but clear suppression of ADP uptake was observed at 20 or 50 
µM, as shown in Fig. 7.  It should be emphasized that the ADP uptake via the 
ADP/ATP carrier observed in the present experimental condition was not influenced by 
the factors such as an increase in the H
+
 permeability caused by SF6847.  Therefore, a 
moderate but specific inhibitory effect of KH-7 on the mitochondrial ADP/ATP carrier 




To examine whether a certain compound has an inhibitory effect on the mitochondrial 
ADP/ATP carrier, we can simply evaluate its direct action on the carrier, as 
demonstrated in the last part of the Results section.  However, it is also very important 
to know whether it shows remarkable side effects on other mitochondrial functions 
aside from the ADP/ATP carrier, especially when we test the compound on the whole 
mitochondria rather than on the isolated ADP/ATP carrier.  Therefore, in the present 
study, we first examined the effects of BKA analogues on mitochondrial ATP synthesis 
and on other properties of mitochondria.  Among the 17 analogues tested, 4 of them, 
i.e., KH-1, -7, -16, and -17, showed inhibitory effects on mitochondrial ATP synthesis.  
Of these, the inhibitory effect of KH-16 on mitochondrial ATP synthesis could hardly be 
attributed to inhibition of ADP/ATP carrier, because it showed remarkable side effects 
on the mitochondrial membrane permeability and respiratory chain.  When we focused 
on the remaining 3 analogues (KH-1, -7, and -17), it became evident that all of them had 
a common left part of their structure, the part consisting of two carboxyl groups.  This 
moiety may have been essential for their inhibitory effects on ADP/ATP carrier, because 
substitution of R1 position of KH-7 with MOM group (i.e., KH-9), caused a loss of the 
inhibitory effects of KH-7.   
Interestingly, moreover, KH-17 had 3 carboxyl groups, like the parental BKA.  It 
should be also emphasized that the length of the alkyl chain connecting left and right 
parts of KH-17 was essentially the same as that of the parental BKA, as schematically 
shown in our recent paper (12).  Therefore, the presence of a third carboxyl group at 
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right part of the molecule, even at a distance from the two carboxyl groups in the left 
part, similar to that of BKA, was a “non-sufficient condition” for strong inhibitory 
effects against ADP/ATP carrier.  When we compared the structures of BKA and 
KH-17, BKA had 3 additional methyl groups and one OMe group.  Inclusion of these 
side chains would be expected to have made the molecule much more hydrophobic.  If 
we assume that the higher hydrophobicity of BKA, especially at the right side of the 
molecule, was necessary for the stronger inhibitory effect on the ADP/ATP carrier, the 
strongest inhibitory effect of HK-7 among the 17 BKA analogues observed in the 
present study becomes explainable, because it has the same left side structure as that of 
BKA, and has a sterically bulky hydrophobic group, the tert-butyl diphenylsilyl 
(TBDPS) group, as the right part of the structure.  However, it should be mentioned 
that other analogues sharing the same right and left parts of the molecule as those of 
KH-7, but having different alkyl chain lengths, such as KH-1 and KH-4, showed weak 
or no inhibitory effects on the mitochondrial ADP/ATP carrier.  A possible explanation 
for the different activities of these analogues is that the presence of this TBDPS group at 
an appropriate distance from the left part of the structure containing the two carboxyl 
groups, was important for the inhibitory action on the ADP/ATP carrier.  To validate 
these interpretations, further structure-activity relationship studies, using analogues 
lacking the TBDPS group as a negative control, would seem to be required.   
One of the remarkable characteristics observed for KH-7 was its pH-independent 
inhibitory action toward the ADP/ATP carrier.  We would like to consider why KH-7 
showed such a unique property.  As clearly mentioned in the past study (19), for the 
inhibition of the ADP/ATP carrier, BKA must be translocated to the matrix side of the 
mitochondrial inner membrane; and for efficient translocation across the mitochondrial 
inner membrane, the carboxyl groups of the BKA molecule should not be dissociated 
(i.e., only the neutral form of BKA can be easily translocated to the matrix side of the 
mitochondrial inner membrane).  Therefore, loss of pH-dependence in the inhibitory 
action on the ADP/ATP carrier observed with KH-7 could be attributable to the absence 
of the carboxyl group in its right part.  In addition, lack of this third carboxyl group in 
its right part may also have significantly weakened the inhibitory action of KH-7 toward 
the ADP/ATP carrier.  To examine these possibilities, a further study on the 
structure/activity relationship of BKA analogues, such as that examining the BKA 
molecule just lacking its right carboxyl group or that evaluating the KH-7 derivative 
having the right carboxyl group, would seem to be necessary.   
In the present study, we successfully identified KH-7 as a new analogue of BKA.  
Although the parental BKA molecule is hard to synthesize and shows strong pH 
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dependence in its action, synthesis of KH-7 was much easier (12); and this analogue did 
not show strong pH dependence.  Although KH-7 showed a much weaker inhibitory 
effect on the mitochondrial ADP/ATP carrier than BKA, its action was specific for the 
carrier.  Thus, KH-7 could be nice tool to understand the catalytic mechanism of the 
mitochondrial ADP/ATP carrier.   
Presently, we only focused on the inhibitory effects of BKA analogues on its primary 
target protein, i.e., the mitochondrial ADP/ATP carrier.  However, BKA is also thought 
to work as an inhibitor of mitochondrion-dependent apoptosis, because it largely 
suppresses the mitochondrial permeability transition (20), which causes the release of 
mitochondrial cytochrome c (a trigger of apoptosis), into cytosol.  Thus, studies on 
BKA analogues are important for possible development of therapeutics for the treatment 
of certain mitochondrion-dependent diseases.   
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 X n Alias or reference  
KH-1 H Si(
t
Bu)Ph2 H,H 6 18a 
KH-2 CH2CH2CN Si(
t
Bu)Ph2 H,H 6 21a 
KH-3 CH2OCH3 Si(
t
Bu)Ph2 H,H 6 17a 
KH-4 H Si(
t
Bu)Ph2 H,H 8 18b 
KH-5 CH2CH2CN Si(
t
Bu)Ph2 H,H 8 21b 
KH-6 CH2OCH3 Si(
t
Bu)Ph2 H,H 8 17b 
KH-7 H Si(
t
Bu)Ph2 H,H 10 18c 
KH-8 CH2CH2CN Si(
t
Bu)Ph2 H,H 10 21c 
KH-9 CH2OCH3 Si(
t
Bu)Ph2 H,H 10 17c 
KH-10 CH2OCH3 Si(
t
Bu)Me2 H,H 10 27a 
KH-11 CH2OCH3 SiPh3 H,H 10 27b 
KH-12 CH2OCH3 CPh3 H,H 10 27c 
KH-13 CH2OCH3 H H,H 10 28 
KH-14 CH2OCH3 CH2OCH3 O 10 35 
KH-15 H H O 10 ref. 12 
KH-16 CH2OCH3 H O 16 ref. 12 
KH-17 H H O 16 ref. 12 
This table summarizes the structural properties of the 17 BKA analogues (see Fig. 1A 
for their general structure).  The symbols with “KH-xx” represent the names of the 




”, and “X” 
are the substituents of the individual chemicals at these positions.  The numbers shown 
in column “n” represent the number of repeated alkyl chain.  The actual structure of 




, X, and n are H, Si(
t
Bu)Ph2, H2, and 10, 
respectively, is shown in Fig. 1B.  The codes or reference No. shown in the column 
“Alias or reference” indicate the alias of individual chemicals used in the process of 
their synthesis (see Schemes 1 and 2) or the reference No. for a study in which the 
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Legends for Schemes and Figures 
 
Scheme 1.  Outline of the procedure used for the synthesis of KH-1~9.   
 
Scheme 2.  Outline of the procedure used for the synthesis of KH-10~14. 
 
Fig. 1.  General structure of the BKA analogues used in the present study (A) and 
chemical structure of KH-7 (B) and parental BKA (C)  





, X, or chain length n of individual analogues, see Table I.   
 
Fig. 2.  Experimental procedure to evaluate inhibitory effects of BKA analogues 
on mitochondrial ATP synthesis  
The experimental system used to evaluate the effects of BKA analogues on the 
mitochondrial ATP synthesis is shown.  Broken line indicates the changes in the pH of 
the incubation medium without the addition of ADP and BKA analogues (negative 
control), and dotted line indicates the changes in the pH of the incubation medium 
caused by the addition of ADP in the absence of BKA analogues (positive control).  
The left and right traces represent the typical results of the experiments at pH 7.4 and 
6.8, respectively.   
 
Fig. 3.  Inhibitory effects of BKA analogues on mitochondrial ATP synthesis   
Inhibitory effects of individual BKA analogues at 1 µM (white column) or 10 µM 
(black column) on mitochondrial ATP synthesis were examined by measuring the 
suppression of the pH change caused by the addition of ADP at pH 6.8.  The results 
obtained by 3 independent runs are shown as % inhibition of ATP synthesis (mean ± 
SD).  The rate of the ATP synthesis in the absence of BKA analogues (i.e., positive 
control in Fig. 1B) was 297 ± 46 nmol/mg/min.   
 
Fig. 4.  Evaluation of the permeabilization effects of the 4 BKA analogues on the 
mitochondrial inner membrane  
Panel A presents the experimental system used for evaluation of permeabilization of the 
mitochondrial inner membrane.  The very slow oxygen consumption observed in the 
absence of added chemicals (broken line) and the rapid oxygen consumption caused by 
the addition of SF6847 (dotted line) indicated the mitochondrial inner membrane 
showing lowest and highest permeability, respectively.  Panel B shows the effects of 
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the BKA analogues on the rate of mitochondrial oxygen consumption.  The rates of 
oxygen consumption observed in the absence of chemicals or in the presence of SF6847 
are shown as hatched columns.  Those observed in the presence of BKA or its 
analogues at 1 and 10 µM are shown with white and black columns, respectively.  The 
bars represent the SD values of individual experiments.   
 
Fig. 5.  Evaluation of the inhibitory effects of BKA analogues on the 
mitochondrial electron transport system  
Panel A outlines the experiment used to evaluate the inhibitory effects of BKA on the 
mitochondrial electron transport system.  The solid line shows the result obtained in 
the absence of BKA; and the broken line, that in the presence of 10 µM BKA.  Panel B 
shows the inhibitory effect of BKA and its analogues on the SF6847-stimulated oxygen 
consumption.  The results observed in the presence of BKA and its analogues at 1 or 
10 µM are shown with white and black columns, respectively.  The bars represent the 
SD values of individual experiments.  The maximum rate of oxygen consumption 
observed in the absence of BKA or its analogue (trace “control” in panel A) was 141 ± 
17 natomsO/mg/min.   
 
Fig. 6.  Comparison of the pH dependency of the inhibitory effects of BKA and 
KH-7 on ATP synthesis 
Inhibitory effects on the mitochondrial ATP synthesis of BKA and KH-7 at various 
concentrations in three incubation media of pH 6.3, 6.8, and 7.4 were examined by 
measuring the pH of the incubation medium as stated in Fig. 1.  Rates of ATP synthesis 
in the absence of BKA or KH-7 (i.e., control) at pH 6.3, 6.8, and 7.4 were 174 ± 22, 297 
± 46, and 384 ± 36 nmol/mg/min, respectively.   
 
Fig. 7.  Direct inhibitory effects of KH-7 on the mitochondrial ADP/ATP carrier 
For evaluation of the direct effects of KH-7 on the mitochondrial ADP/ATP carrier, 
uptake of ADP was measured by using [
3
H]ADP as a tracer.  ADP uptakes observed in 
the absence (none) and presence of an inhibitor (CATR or BKA at 10 µM) were used as 
positive and negative controls, respectively.  For details of experiments, see the 
Methods section.   
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